Wall Street Zen Upgrades Tenax Therapeutics (NASDAQ:TENX) to Sell

Tenax Therapeutics (NASDAQ:TENX) was upgraded by analysts at Wall Street Zen to a “sell” rating in a report issued on Saturday.

Several other brokerages also recently issued reports on TENX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tenax Therapeutics in a research report on Tuesday, October 14th. Guggenheim cut their price target on Tenax Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, August 14th. Finally, Piper Sandler started coverage on Tenax Therapeutics in a research note on Monday, September 8th. They set an “overweight” rating and a $20.00 price target on the stock. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $18.00.

Tenax Therapeutics Stock Performance

Shares of TENX opened at $7.39 on Friday. The stock has a fifty day moving average price of $6.65 and a two-hundred day moving average price of $6.12. Tenax Therapeutics has a 52-week low of $4.30 and a 52-week high of $8.24. The company has a market cap of $33.70 million, a price-to-earnings ratio of -8.03 and a beta of 1.58.

Tenax Therapeutics (NASDAQ:TENX) last issued its quarterly earnings data on Wednesday, August 13th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.23. As a group, research analysts predict that Tenax Therapeutics will post -0.88 EPS for the current fiscal year.

Institutional Investors Weigh In On Tenax Therapeutics

An institutional investor recently raised its position in Tenax Therapeutics stock. ADAR1 Capital Management LLC boosted its stake in Tenax Therapeutics, Inc. (NASDAQ:TENX) by 98.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 68,741 shares of the specialty pharmaceutical company’s stock after purchasing an additional 34,048 shares during the quarter. ADAR1 Capital Management LLC owned about 1.66% of Tenax Therapeutics worth $450,000 as of its most recent SEC filing. 1.67% of the stock is owned by institutional investors and hedge funds.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.